{"id":46826,"date":"2022-08-02T14:02:04","date_gmt":"2022-08-02T12:02:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/"},"modified":"2022-08-02T14:02:04","modified_gmt":"2022-08-02T12:02:04","slug":"endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/","title":{"rendered":"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices"},"content":{"rendered":"
\n

\nTAEUS\u00ae<\/sup> now protected by 53 patents issued globally, including 31 in the U.S.<\/i>\n<\/p>\n

\nN<\/i>ew U.S. patents expand potential licensing opportunities in data management<\/i>\n<\/p>\n

ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA<\/a> #NALFD<\/a>—ENDRA Life Sciences Inc.<\/a> <\/b>(NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae<\/sup>), announces that the United States Patent & Trademark Office has issued three new patents to ENDRA including U.S. Patent No. 11379343 (the \u2018343 patent), U.S. Patent No. 11392479 (the \u2018479 patent) and U.S. Patent No. 11405470 (the \u2018470 patent). All three patents are titled \u201cMethods and Systems for Exchange of Equipment Performance Data.\u201d\n<\/p>\n

\n\u201cWe are pleased to be issued these three patents that, along with a previously issued U.S. patent, provide broad protection for our proprietary method to transfer equipment performance data to cloud-based services. In addition to protecting data management for our TAEUS system, these patents provide licensing opportunities with other equipment manufacturers,\u201d stated ENDRA’s Chairman and Chief Executive Officer Francois Michelon. “We continue to enhance our intellectual property portfolio to protect our technology in priority global markets. Our portfolio currently includes 53 patents issued globally, of which 31 patents are issued in the U.S.\u201d\n<\/p>\n

\nThese three newly issued patents are part of a patent family that protects ENDRA\u2019s proprietary method and system for acquiring, analyzing and sharing data in the cloud. The \u2018343 and \u2018479 patents protect ENDRA’s data sharing capabilities that are specific to the medical imaging industry. The \u2018470 patent builds upon the company\u2019s U.S. Patent No. 11314617 (the \u2018617 patent). Both the \u2018470 and \u2018617 patents have claims that are narrower than the \u2018343 and \u2018479 patents and apply to industries outside of medical imaging. The \u2018470 patent broadens ENDRA\u2019s coverage from devices \u201cnot having internet connectivity\u201d (as described in the \u2018617 patent) to devices that are \u201ccommunicatively insulated.\u201d\n<\/p>\n

\nAbout ENDRA Life Sciences Inc.<\/b>\n<\/p>\n

\nENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae<\/sup>), a ground-breaking technology being developed to visualize tissue like MRI, but at 1\/50th<\/sup> the cost and at the point of patient care. TAEUS\u00ae<\/sup> is designed to work in concert with over 500,000 ultrasound systems in use globally today. TAEUS\u00ae<\/sup> is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS\u00ae<\/sup>, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nAll statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as \u201capproximate,\u201d “anticipate,” \u201cattempt,\u201d “believe,” “could,” “estimate,” “expect,” \u201cforecast,\u201d \u201cfuture,\u201d “goal,” \u201chope,\u201d “intend,” “may,” “plan,” \u201cpossible,\u201d \u201cpotential,\u201d \u201cproject,\u201d “seek,” “should,” “will,” \u201cwould,\u201d or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing for receipt of required regulatory approvals and product launches; future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; ENDRA\u2019s ability to find and maintain development partners; market acceptance of ENDRA\u2019s technology and the amount and nature of competition in its industry; and ENDRA\u2019s ability to protect its intellectual property. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA\u2019s business plans; the ability to find and maintain development partners; market acceptance of ENDRA\u2019s technology and the amount and nature of competition in its industry; ENDRA\u2019s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management\u2019s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company\u2019s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nIrina Pestrikova
\n
Senior Director, Finance
\n
investors@endrainc.com<\/a>
www.endrainc.com<\/a>\n<\/p>\n

\nInvestor Relations:
\n
Yvonne Briggs
\n
LHA Investor Relations
\n
(310) 691-7100
\n
YBriggs@lhai.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TAEUS\u00ae now protected by 53 patents issued globally, including 31 in the U.S. New U.S. patents expand potential licensing opportunities in data management ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NALFD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae), announces that the United States Patent & Trademark Office has issued … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46826","6":"format-standard","7":"category-industry"},"yoast_head":"\nENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TAEUS\u00ae now protected by 53 patents issued globally, including 31 in the U.S. New U.S. patents expand potential licensing opportunities in data management ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NALFD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae), announces that the United States Patent & Trademark Office has issued ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-02T12:02:04+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices\",\"datePublished\":\"2022-08-02T12:02:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/\"},\"wordCount\":882,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/\",\"name\":\"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-08-02T12:02:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/","og_locale":"en_US","og_type":"article","og_title":"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices - Pharma Trend","og_description":"TAEUS\u00ae now protected by 53 patents issued globally, including 31 in the U.S. New U.S. patents expand potential licensing opportunities in data management ANN ARBOR, Mich.–(BUSINESS WIRE)–$NDRA #NALFD—ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS\u00ae), announces that the United States Patent & Trademark Office has issued ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-02T12:02:04+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices","datePublished":"2022-08-02T12:02:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/"},"wordCount":882,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/","url":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/","name":"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-08-02T12:02:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/endra-life-sciences-awarded-three-additional-u-s-patents-for-cloud-enabled-connectivity-of-medical-devices\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46826","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46826"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46826\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46826"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46826"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}